Scribd
Upload
164 views1 page

Genome Sciences Building SID: CTTP-005-8551 Final - Approved 01/14/2021 5:10PM Collected: 01/13/2021 1:39PM

James Crescenzi underwent COVID-19 testing on January 13, 2021. His test was processed using real-time PCR and was found to be negative for SARS-CoV-2. The test has received FDA emergency use authorization and while a negative result makes infection less likely, it does not rule it out completely due to potential issues with sample collection or low viral load. Crescenzi should continue following CDC and university guidelines to prevent potential infection. The test was performed at the UNC Genome Sciences Building laboratory.

Uploaded by

James C.
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
164 views1 page

Genome Sciences Building SID: CTTP-005-8551 Final - Approved 01/14/2021 5:10PM Collected: 01/13/2021 1:39PM

James Crescenzi underwent COVID-19 testing on January 13, 2021. His test was processed using real-time PCR and was found to be negative for SARS-CoV-2. The test has received FDA emergency use authorization and while a negative result makes infection less likely, it does not rule it out completely due to potential issues with sample collection or low viral load. Crescenzi should continue following CDC and university guidelines to prevent potential infection. The test was performed at the UNC Genome Sciences Building laboratory.

Uploaded by

James C.
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

LAB REPORT

Printed: 01/14/2021 10:34PM


Patient: Crescenzi, James A. Order Date: 01/13/2021 1:39PM
Gender: M DOB: 08/22/2001 Location: Student Union
UNC PID: 730293742 Order ID: 02983-on-21013
Phone: (919)945-4600 Ordering Provider: Barzin, Amir H., DO

Genome Sciences Building1 SID: CTTP-005-


COVID19 8551
Final - Approved 01/14/2021 5:10PM Collected: 01/13/2021 1:39PM
Testing performed by multiplex real-time PCR using the Thermo Fisher/TaqPath COVID-19 Testing. This test has not been FDA cleared or approved. This test has been
authorized by the FDA under an Emergency Use Authorization (EUA) issue on March 24, 2020 and may be utilized until the emergency use authorization is terminated or
revoked. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.

This test has received FDA Emergency Use Authorization to detect the ORF1ab gene, the N gene and the S gene of SARS-CoV-2 using nucleic acid amplification. A Not
Detected result does not preclude the possibility of 2019-nCoV infection since the adequacy of sample collection and/or low viral burden may result in the presence of viral
nucleic acids below the analytical sensitivity of this test method. Test results should be used along with other clinical and laboratory data in making the diagnosis. Information
for providers can be found https://www.fda.gov/media/136114/download. Information for patients can be found https://www.fda.gov/media/136111/download.

TEST RESULT REFERENCE RANGE


SARS-CoV-2 Not Detected Not Detected
Not Detected: SARS-CoV-2 was NOT detected in your sample. Continue to follow all guidelines set forth by the CDC and the University to minimize the potential for
infection.

Reporting Laboratories:
(1) Genome Sciences Building (CLIA ID: 34D2199730), Lab Director: Fiscus, Susan A., PhD, 250 Belltower Dr, Genome Sciences
Bldg, Rm 2344, CB 7540, Mailbox 4, Chapel Hill, NC 27599, 919-966-0350
Results sent to: Hall Pass (Host Interface)
State Reportables (Host Interface)

Lab Report REPRINT: Orig. printing on 01/14/2021 Page 1 of 1 Crescenzi, James A., Order ID: 02983-on-21013

You might also like